Compare OPTH & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | OPTH | GRML |
|---|---|---|
| Founded | 2020 | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.9M | 29.2M |
| IPO Year | 2024 | 2022 |
| Metric | OPTH | GRML |
|---|---|---|
| Price | $3.25 | $5.86 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 25.4K | ★ 6.0M |
| Earning Date | 12-08-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $56.17 | N/A |
| Revenue Next Year | $82.70 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.04 | $0.16 |
| 52 Week High | $5.45 | $18.21 |
| Indicator | OPTH | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 27.97 | 47.10 |
| Support Level | $3.04 | $0.28 |
| Resistance Level | $5.21 | $7.53 |
| Average True Range (ATR) | 0.32 | 0.85 |
| MACD | -0.04 | -0.28 |
| Stochastic Oscillator | 10.00 | 34.48 |
Optimi Health Corp operates in developing a vertically integrated Canadian functional mushroom brand that focuses on the health and wellness sector. The company has one reportable operating segment being that of the farming, processing, and distribution of raw mushroom biomass. It also intends to cultivate, extract, process, and distribute strains of fungi products at its facilities located in Princeton, British Columbia.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.